Please use this identifier to cite or link to this item:
|Title:||Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B.|
|Authors:||Ng, Steven Y;Villemagne, Victor L;Masters, Colin L;Rowe, Christopher C|
|Affiliation:||Department of Nuclear Medicine and Centre for Positron Emission Tomography, Austin Health, Melbourne, Australia.|
|Citation:||Archives of Neurology; 64(8): 1140-4|
|Abstract:||A progressive decline in episodic memory affecting activities of daily living is the usual clinical presentation of Alzheimer disease. However, patients presenting with atypical or focal clinical symptoms such as language or visuospatial dysfunction often pose a diagnostic challenge.To explore the presence and topography of beta amyloid (Abeta) as measured by carbon 11-labeled Pittsburgh Compound B ((11)C-PiB) in patients with atypical presentations of dementia.At a tertiary referral center for memory disorders, 15 healthy controls, 10 patients with Alzheimer disease, a patient with primary progressive aphasia (PPA), and a patient with posterior cortical atrophy (PCA) underwent (11)C-PiB positron emission tomographic studies. Retention of (11)C-PiB was compared between different groups using statistical parametric mapping.The topography of cortical (11)C-PiB binding in atypical vs typical Alzheimer disease.Cortical (11)C-PiB binding was higher in the group with Alzheimer disease and in the patients with PPA and PCA than the controls (P < .001). Both patients with atypical dementia had a similar (11)C-PiB binding pattern to Alzheimer disease although (11)C-PiB retention was higher on the left cerebral hemisphere in the patient with PPA (P < .01) and higher in the occipital cortex in the patient with PCA (P < .01).The presence of distinctive focal (11)C-PiB retention patterns was demonstrated in 2 patients with atypical onset of dementia. Pittsburgh Compound B has the potential to facilitate differential diagnosis of dementia and identify patients who could benefit from specific therapeutic strategies aimed at beta amyloid reduction.|
|Internal ID Number:||17698704|
Alzheimer Disease.metabolism.radionuclide imaging
Aniline Compounds.diagnostic use
Aphasia, Primary Progressive.metabolism.radionuclide imaging
Carbon Radioisotopes.diagnostic use
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.